Frontlight ResearchEarly access
CompletedPhase 2
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
Key facts
- Who runs it
- Charite University, Berlin, Germany
- Where
- Germany4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 170 people enrolled
- Started
- 1 Oct 2020
- Ended
- 2 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BX-1
- Placebo
- Record updated
- 13 August 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Diagnosis of posttraumatic stress disorder (PTSD) according to DSM 5 with a 20 item CAPS-5 total score ≥ 26
- At least two nightmares a week, an intensity score ≥ 2, with a CAPS-IV B2 (frequency and intensity for the last week) score ≥ 5
- Men and women between 18 and 65 years of age
- Written informed consent
- The patient has the capacity to give consent (He/she is able to understand the nature and anticipated effects/side effects of the proposed medical intervention)
- The patient is not breastfeeding
- Women of child-bearing potential must have a negative urine or serum pregnancy test
- All participants must use highly effective contraception
- The patient received stable pharmacological medication for at least 4 weeks prior to study entry (any changes in medication dose or frequency of therapy must be answered with no)
Who cannot take part
- Trauma-focused psychotherapy four weeks before the trial
- Initiation of sleep medication 4 weeks prior screening or initiation of alpha adrenergic agents 4 weeks prior to screening
- The patient did participate in other interventional trials during the 3 months before and at the time of this trial
- Lifetime cannabis use disorder
- Current substance/alcohol use disorder (≤ 3 months)
- Psychotic disorder
- Bipolar disorder
- Dementia
- Acute or unstable medical illness
- Epilepsy
- Relevant heart diseases
- Known HIV- and/or active Hepatitis-B- or Hepatitis-C-infection
- Current or past malignant illness
- The patient does have a known allergy or contraindication against Dronabinol
- The patient does have clinically significant laboratory abnormalities
- Acute suicidality
- Current anorexia nervosa
- Current major depressive episodes and a MADRS score > 29
- The patient is unwilling to consent to saving, processing and propagation of pseudonymized medical data for study reasons
- Patients, who may be dependent on the sponsor, the investigator or the trial sites, have to be excluded from the trial
- The patient is legally detained in an official institution
- The patient does have clinically significant abnormalities in 12-lead ECG
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled exploratory phase II trial will test the hypothesis that oral dronabinol improves nightmares (primary outcome) and other PTSD symptoms (secondary outcomes) to a greater extent than placebo over a ten week intervention phase in a parallel group design.
The 2 groups in the trial
- BX-1 (dronabinol)Treatment being tested
BX-1
Treatment: BX-1
- PlaceboPlacebo, for comparison
Placebo of BX-1
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol: A Randomized Controlled Study (THC PTSD-trial)
- Publications
- Record updated
- 13 August 2025